Details for New Drug Application (NDA): 019038
✉ Email this page to a colleague
NDA 019038 describes CALAN, which is a drug marketed by Gd Searle Llc and Pfizer and is included in three NDAs. Additional details are available on the CALAN profile page.
The generic ingredient in CALAN is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
The generic ingredient in CALAN is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Summary for 019038
| Tradename: | CALAN |
| Applicant: | Gd Searle Llc |
| Ingredient: | verapamil hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 019038
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 2.5MG/ML | ||||
| Approval Date: | Mar 30, 1984 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
